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Editorial
Although still the most common female cancer worldwide, including 
Hong Kong, the outlook for patients diagnosed with breast cancer 
has been changing for the better over time, with several significant 
advances coming through in the past 10 years.  
New technology in breast imaging has allowed an earlier and more 
accurate diagnosis of breast cancer not only to improve outcome 
but also for better treatment planning.  In the era of genomics and 
with the study of epidemiology of breast cancer, there is increasing 
understanding of the risks of breast cancer. This has allowed a different 
approach to individuals who are at risk particularly due to hereditary 
germline mutations to opt for primary and secondary prevention 
interventions. 
Earlier diagnosis has allowed less invasive surgery, moving from 
mastectomy to breast conservation surgery and with the evolvement 
of the use of oncoplastic surgery and breast reconstruction technique, 
the cosmetic outcome of women who have to undergo breast cancer 
surgery are much more satisfactory. The increased indications of use of 
sentinel lymph node biopsy and lesser indications of axillary dissection 
will result in less complications associated with the procedure such as 
lymphoedema. 
With the past 10 years of progress in breast cancer treatment and 
research, women facing the disease today have many promising 
options as therapies become more tailored to particular disease types 
and are designed to minimise side effects. HER2-directed therapies 
have revolutionised the treatment of HER2-positive breast cancer 
and have reduced recurrence risks in early-stage disease and also 
increased response at neoadjuvant settings. Gene expression testing 
helps determine a patient’s risk of recurrence or metastasis based on 
the types of genes that the cancer expresses (gene subtyping) and to plan 
treatment to most effectively reduce this risk. Specifically, these tests 
help determine which patients are more likely to benefit from treatment 
with chemotherapy in addition to hormonal therapy and hence also 
select those patients who may not actually need chemotherapy. We also 
have better drugs and better combinations of drugs to reduce toxicities 
and yet not compromising the outcomes. State-of-the-art radiation 
treatment using sophisticated machines and techniques allows the 
sparing of the heart, lung and skin from being damaged while targeting 
the breast cancer. A multidisciplinary approach of managing breast 
cancer patients including not only medical care but also holistic care has 
given women with breast cancer a much brighter future.
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FRCS, FHKAM (Surgery), FCSHK
Assistant Dean, The University of Hong Kong
Clinical Associate Professor, Chief of Breast Surgery Division, 
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Breast cancers in Hong Kong – an overview from 
the Hong Kong Cancer Registry
Dr Roger KC NGAN 
FRCR, FHKAM (Radiology)
Director, Hong Kong Cancer Registry
Dr Roger KC NGAN 
With an ageing population, the number of new cancers 
diagnosed per year has been increasing over the 10 year 
period from 2002 to 2012. According to the latest cancer 
statistics published in last November for the year 2012 
from the Hong Kong Cancer Registry, there has been a 
27% increase in the number of new cancers over the 10 
year period, from 21,861 in year 2002 to 27,848 in year 
2012.1 Although the 3rd place ranking in new cancer 
numbers for breast cancer has remained unchanged 
(behind lung and colorectal cancers in both 2002 
and 2012), its magnitude of increase at 70% over the 
same period was the highest among the top 3 cancers. 
Fortunately, the number of cancer deaths has risen less 
sharply by 41%, from 427 deaths in year 2002 to 604 
deaths in 2012.1 (Table 1)
Table 1 New cancer cases and deaths in Hong Kong (2012) 
(Source: Hong Kong Cancer Registry)
Indeed, considering the rate of growth and actual 
numbers together, breast and colorectal cancers have 
been identified as the 2 most rapidly growing cancers 
over the past 2 decades (1993 – 2012), both of which are 
resource-draining for treatment. (Figure 1) According to 
the cancer statistics of the Hong Kong Cancer Registry, 
they are paralleled to a lesser extent by lung cancer. The 
rise in new breast cancer numbers could be accounted 
for by the growing and ageing Hong Kong female 
population on one hand, and also a genuine increase in 
the risk of breast cancer on the other, as exemplified by 
an annual percentage increase of 2.4% per year over the 
same 20 year period for the age-standardised incidence 
(ASI). The ASI has already taken into account the age-
specific incidences of a cancer for different age groups in 
the population of a particular region having specific age 
distribution, by applying these age-specific incidences 
to a standard world population, and therefore its 
change over time for a particular region is indicative 
of a genuine change of risk of developing the cancer 
irrespective of ageing or growth of the population in 
that region. 
Figure 1 Trends of newly diagnosed numbers of cancers in 
Hong Kong since 1993 (Source: Hong Kong Cancer Registry)
The rise in ASI of breast cancer in Hong Kong might be 
attributed to a multitude of factors, namely westernised 
diet, life style changes, lack of exercise, reduced parity 
and breast feeding, etc, among others.2 Despite the 
noticeable growth in cancer burden and ASI, the ASI of 
breast cancer of Hong Kong, at 56.7 per 100,000 in 2012, 
is still way below that of the West represented by the 
US (92.9 per 100,000) and UK (95 per 100,000).3 Our ASI 
is even lower than that of Singapore (65.7), and is only 
slightly higher than that of Korea (52.1) and Japan (51.5).3 
(Table 2)
Table 2 Age-standardised incidence and mortality of 
different countries or cities in the world (estimates in 2012)
Country/City Age-standardised 
Incidence (per 
100,000)
Age-standardised 
Mortality (per 100,000)
Japan 51.5 9.8
South Korea 52.1 6.1
Hong Kong* 56.7 8.6
Singapore 65.7 15.5
Canada 79.8 13.9
Australia 86.0 14.0
Germany 91.6 15.5
USA 92.9 14.9
United Kingdom 95.0 17.1
Source: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: 
IARC CancerBase No. 11. Lyon, France: International Agency for Research on 
Cancer; 2013.
*Hong Kong Cancer Registry 2012 actual figures.
Indeed, breast cancer is the commonest cancer among 
females in Hong Kong, with more than 3,500 new breast 
cancers diagnosed in 2012.1 The median age of diagnosis 
was 54, and it was the commonest cancer in the age 
groups ranging from 20 to 74. Among the different age 
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groups, increases in the number of new breast cancers 
have been most noticeable in the age groups of 45 – 54 
and 55 – 64. Based on the trends of age-specific breast 
cancer incidences and the anticipated age distribution 
of the Hong Kong female population according to the 
Hong Kong Census Department, the Hong Kong Cancer 
Registry is projecting a record number of around 6,000 
new breast cancers to be diagnosed in year 2030. 
Breast cancers accounted for more than 600 deaths in 
2012, the median age at death being 59.1 Fortunately, 
despite an increase in ASI at 2.4% per year over the 
past 20 years, the age-standardised mortality (ASM) 
has remained largely stable over the same period. 
The observation is also mirrored by the Surveillance, 
Epidemiology and End Result programme (SEER) report 
of an improvement in overall survival in breast cancer 
patients in the US.4 There are a number of good reasons 
contributing to the apparent survival improvement in 
Hong Kong – introduction of more effective treatments 
accessible to the majority, better medical supportive 
therapy, more early stages at presentation due to 
frequent opportunistic screening and public awareness, 
and better health condition and improving longevity of 
the Hong Kong population at large.
We reported in 2011 survivals of 7,500 patients with 
breast cancer diagnosed from 1997 – 2001 in the 
population of Hong Kong.5 The 5 year relative survival, 
cause-specific survival and disease-free survival 
were 84%, 85.2% and 81.2% respectively. Stage 1 and 
stage 2 patients’ 5 year relative survivals (97% & 89% 
respectively) were far better than those of stage 3 and 
stage 4 patients (68% & 19% respectively), underscoring 
the importance of early diagnosis. In a subsequent 
analysis of another 10,600 patients diagnosed in the 
years 2002 – 2006, the 5 year relative survival of the 
whole group was around 86%. (unpublished data) The 
85.6% 5 year relative survival observed for the whole 
group of ~18,100 patients diagnosed over the 10 year 
period from 1997 – 2006 in Hong Kong was similar to 
the 5 year survivals reported by the cancer registries of 
Taiwan and Korea (82.9% and 88.5% respectively) and 
SEER (87.1%) over the same period.6-8
With a view to elucidating the clinical profiles of the 
breast cancers diagnosed in Hong Kong in recent years 
to understand the epidemiology and their relevance to 
survival outcomes, the Hong Kong Cancer Registry has 
started collecting key clinical data since about 10 years 
ago. In a cohort of more than 9900 patients diagnosed 
in Hong Kong during the period of 2010 – 2012, two-
thirds were diagnosed of stage I or II cancers, 21% 
presented with stage III or IV cancers while 12.2% had 
unconfirmed stages. Among those patients, hormonal 
and/or human epidermal receptor-2 (HER-2) status were 
unknown in about 9%; 68% had oestrogen-receptor (ER) 
positive cancers, 53% had progesterone (PR) positive 
cancers, and 23% had HER2 positive cancers. With 
regard to the treatments delivered, 24% of those ~8,800 
patients in whom the clinical data of both chemotherapy 
and radiotherapy treatments could be confirmed 
received neither chemotherapy nor radiotherapy 
after surgery. On the other hand, 39% patients had 
received both chemotherapy and radiotherapy, while 
16% and 22% patients had received chemotherapy and 
radiotherapy alone respectively. (unpublished data)
In the foreseeable future, breast cancer will still be the 
most common cancer in Hong Kong females, posing 
a significant threat to the female population and the 
health care providers in both the public and private 
sectors despite a noticeable improving survival. The 
Hong Kong Cancer Registry of the Hospital Authority 
will be scaling up its strenuous efforts in collecting 
accurate and clinically relevant cancer-related data of all 
breast cancers diagnosed in Hong Kong, with a view to 
serving its role in cancer control in accordance with the 
International Association of Cancer Registries (IACR) 
of which we are a voting member, providing timely 
data to planners of health care strategies for breast 
cancer control, and collaborating with researchers in 
epidemiology and outcome studies. 
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There are many environmental and epidemiological 
factors which will increase the risks of breast cancer 
and ovarian cancer such as the adaptation of a Western 
lifestyle and hormonal related factors. Around 15-20% 
of women who develop breast cancer have a family 
history, in what is known to be “familial” and another 
5-10% a true genetic predisposition, that is “hereditary”. 
Although it is not the most common cause, there is no 
other risk predictor which is as strong as an inherited 
mutation such as tumour-suppressor genes BRCA 1 
and BRCA 2 being the most common hereditary genes 
related to breast cancer. A mutation in one of the BRCA 
genes can significantly increase the lifetime risk of breast 
cancer to 40-80%, and that of ovarian cancer from 11-
40%. Men carrying such mutations would have 1-10% 
lifetime risk of getting breast cancer and up to 39% 
may also have prostate cancer. Apart from BRCA 1 and 
BRCA 2 mutations, several less penetrant genes and less 
common genes such as PTEN, TP53 and recently PALB2 
have been identified, which when mutated, result in a 
significant increased risk of breast cancer as well as other 
cancers such as sarcoma, leukaemia and brain tumour for 
TP53, and thyroid cancer for PTEN. Such genes follow 
the autosomal dominant pattern of transmission, hence 
alterations in these genes can be passed down from 
either the paternal or maternal side. The probability 
of an offspring carrying the mutation is therefore 50 
percent and genotypically there cannot be any “skip 
generations” in the inheritance. Knowing the genetic risk 
is as important as the environmental risks, as it is the 
interactions of the risks predisposed by these mutated 
genes with environmental and lifestyle modifiers that 
result in the phenotypic presentation of cancer.
Timely identification and periodic screening of high 
risk individuals may allow early detection of breast 
and other cancers, improve prognosis and treatment 
outcomes. There is growing evidence that breast and 
ovarian cancers are preventable in women with a 
BRCA1 or BRCA2 mutation. Although to date there is 
no supporting evidence on the benefits in the overall 
survival, prophylactic mastectomy is known to reduce 
the risk of breast cancer by 80% in women with a family 
history of breast cancer and by 89% risk reduction in 
women with a BRCA1 or BRCA2 mutation.  Prophylactic 
salpingo-oophorectomies not only reduce the risk of 
ovarian/fallopian/peritoneal cancers by ~80% in women 
with a BRCA1 or BRCA2 mutation but it has also been 
shown to reduce the risk of breast cancer. For women 
who had preventive surgeries before age 40, a 50% risk 
reduction in breast cancer has been observed. Moreover, 
a prophylactic salpingo-oophorectomy has been found 
to reduce ovarian and breast cancer related mortality 
and all cause mortality in BRCA mutation carriers. The 
effectiveness of tamoxifen for primary prevention of 
breast cancer in BRCA1 carriers is not yet proven and its 
use in this setting is not widespread. However, tamoxifen 
has been shown to reduce the risk of contralateral breast 
cancer in both BRCA1 and BRCA2 carriers by 50%. 
Other agents which have been used for prevention of 
breast cancer include Raloxifene and there are ongoing 
studies on the use of aromotase inhibitors and other 
agents in the prevention setting being performed.  If an 
individual does not opt for active prevention measures, 
she may be offered alternate screening interventions, 
including the choice of intensive breast surveillance 
(MRI breasts in addition to standard breast imaging such 
as mammography and ultrasonography) and ovarian 
screening including ovarian ultrasonography, CA125 and 
pelvic examination. 
Table 1 NCCN Management of the hereditary breast and/or 
ovarian cancer syndrome
(Adapted from the NCCN guidelines, version 2.2014)
Hereditary breast and/or ovarian cancer syndrome management 
(NCCN guidelines) 
• Breast screening
› Annual breast MRI screening or mammogram for aged 25-29y/
breast MRI screening and mammogram for aged ≥35-70y/individual 
consideration for aged >70y
• Risk-reducing mastectomy
› Counselling may include a discussion regarding degree of protection, 
reconstruction option and risks
• Risk-reducing salpingo-oophorectomy is recommended for those 
aged 35-40y and upon completion of child bearing
› Counselling may include a discussion of reproductive desires, extent 
of cancer risk, degree of protection for breast and ovarian cancer, 
management of menopausal symptoms
• Address the psychosocial, social and quality-of-life aspects 
• For those who have not  selected r isk-reducing salpingo-
oophorectomy, consider concurrent transvaginal ultrasound and CA-
125 monitoring starting at 30y or 5-10y before the earliest age of first 
diagnosis of ovarian cancer in the family
• Consider chemoprevention for breast cancer and ovarian cancer
• Consider investigational imaging and screening studies
Moreover, apart from the option of taking preventative 
measures, for breast cancer patients, knowing her 
risk status will aid decision treatment options, 
such as the consideration of mastectomy instead of 
breast conservation surgery, options of contralateral 
prophylactic mastectomy and more recently the choice of 
chemotherapy as primary treatments such as the use of 
carboplatin as a neoadjuvant agent and the evolvement 
of the use of targeted therapies, such as PARP inhibitors 
in the near future. 
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The assessment of an individual’s risk for breast cancer 
is therefore complex. Moreover, it is important to give 
sufficient information to patients to aid them in the choice 
of management when the individual is found to be a 
mutation carrier. Therefore, the most important emphasis 
for high-risk individuals should not be put on getting 
the patients to be tested alone but to include genetic 
counselling as an essential part of the consultation. 
Genetic counsellors and clinical geneticist/surgeons 
should enable the patients to weigh the consequences and 
benefits in the context of his/her life and subjective values, 
providing a reassuring environment and counselling that 
leads to autonomous choice suitable for the individual. 
Other hereditary breast cancer 
susceptibility genes and multigene panels
There are other low penetrant genes that are found to be 
associated with hereditary breast cancer which are less 
commonly tested such as STK11, CDH1 and MMR genes, 
being responsible for Peutz-Jeghers and Hereditary 
Diffuse Gastric Cancer and Lynch syndrome respectively. 
Some moderate penetrance genes such as CHEK2, ATM, 
BRIP1, RAD51C, RAD51D, BARD1, MRE11, RAD50, 
NBS1 and FANCM have also been recognised as breast 
cancer susceptibility genes. Recent development of multi-
gene testing and advanced technology in Next-generation 
sequencing enable simultaneous analysis of specific panel 
of genes, and have allowed a flux of multi-gene panel kits 
being created and sold commercially. Although they are 
likely to be beneficial in contributing to prevention and 
possible guidance to drug management in future, there 
are still limited outcome data on clinical interventions 
particularly in lower penetrance gene mutation related 
breast cancers. Therefore results of multigene panels may 
pose difficulty in interpretation and clinical decisions and 
are best left for research settings and use of these panels 
in clinical settings should be decided upon in a case to 
case basis. 
The Hong Kong Hereditary Breast Cancer 
Family Registry
The Hong Kong Hereditary Breast Cancer Family 
Registry was developed in March 2007 as a charitable 
organisation to subsidise those who are underprivileged 
to have the opportunity to undergo genetic testing. The 
Registry has also been collecting data from high risk 
families with consent, to study the mutation spectrum 
in the Chinese population. Together with the Hong 
Kong Hereditary High Risk Breast and Ovarian Cancer 
Programme which is a joint effort of University of Hong 
Kong, Hong Kong Sanatorium and Hospital and Stanford 
University School of Medicine, the programme has 
supported over 1800 families to date for genetic testing 
for risk assessment. Moreover a multidisciplinary team 
of genetic counsellors, nurses, surgeons, oncologists and 
research scientists have contributed to the programme 
to improve the knowledge of hereditary breast, ovarian 
and prostate cancers in our locality. Breast cancer 
patients and/or ovarian cancer patients and more 
recently prostate cancers can now be referred to join the 
programme and where suitable, the testing costs can be 
subsidised. Patients can also contact the registry directly 
to ask for more information about genetic testing and 
trained personnel would be able to guide individuals 
if their genetic testings are suitable and refer them to 
high risk clinics where appropriate. The testing criteria 
are similar to that of international guidelines with some 
adaptations to our locality. Breast cancer patients who (1) 
have at least one 1st or 2nd degree relative with breast 
cancer and/or ovarian cancer; (2) aged 45 years old and 
below; (3) have bilateral breast cancers; (4) have triple 
negative breast cancer; (5) have at least 1 relative with 
BRCA mutation related cancer; (6) are ovarian cancer 
patients with/without a family history of breast cancer; 
(7) have male breast cancer are suitable for testing for 
the BRCA mutations. For families with breast cancer 
and also other types of cancers, their family history will 
be assessed and recommendation of the type of genetic 
testing will be given. Each individual is given a genetic 
counselling process apart from the testing to ensure the 
implications for genetic testing was understood.  The 
gold standard technique BRCA1 and BRCA2 mutations 
by bi-directional Sanger sequencing of all coding exons 
and multiplex ligation-dependent probe amplification 
(MLPA) were initially performed but since 2011 the use 
of next-generation DNA sequencing to expedite analysis 
workflow and expand gene panel to include TP53 and 
PTEN for sequencing has been implanted. The mutation 
screening result of a 4-gene panel BRCA1, BRCA2, TP53 
and PTEN in our recruited patients revealed that 9% 
carried such mutations. To date, a number of recurrent 
and founder mutations have also been identified and 
the Registry has now taken the testing strategy similar 
to that used in Ashkenazi Jews which have three known 
founder mutations and full genes are only tested when 
the recurrent and founder mutations are not detected. 
This has increased the efficiency of our testing so that 
more individuals can benefit from risk assessment.
Conclusion
Hereditary Breast and Ovarian Syndrome only comprises 
10-15 % of all breast and ovarian cancers. However 
with the significant increased risk of cancer, available 
prevention and surveillance strategies, and also targeted 
therapies to mutation carriers being increasingly 
available, it is a syndrome where clinicians should look 
out for and refer to further investigations. 
Appendix: For more information of referrals for genetic 
testing please contact Hong Kong Hereditary Breast 
Cancer Family Registry on www.asiabreastregistry.com 
or email: enquiries@asiabreastregistry.com
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Introduction
Breast imaging is an integral part in the management of 
patients with breast diseases and is a recognised method 
for breast cancer screening.  The common imaging tools 
include mammogram, breast ultrasound and magnetic 
resonance imaging (MRI) of the breasts.  There has been 
a long history in using mammography as screening 
for breast cancers and diagnostic evaluation of breast 
symptoms.  With technological advancement, the newer 
generation mammography with tomosynthesis has 
shown improvements in cancer detection.
Mammography
Mammography is an X-ray examination of the breast. 
The breast is compressed between two compression 
plates to flatten the breast and spread the fibroglandular 
tissue.  Two standard views are usually obtained 
in each breast, namely, the cranio-caudal (CC) and 
medial-lateral oblique (MLO) views.  One projection 
image per breast is obtained from each compression in 
conventional 2D mammogram. Additional views such 
as spot compression may be required to clarify any 
suspicious mass or distortion and a magnified view 
is required for better morphologic characterisation of 
microcalcifications.  The entire procedure of bilateral 
mammography would take about 5-10 minutes.   
Mammography Development
Mammography has been used for more than 50 
years.  In the old days, mammography was performed 
using film screen mammography.  Early results in 
the 1960s were promising and had a true positive rate 
of 79% and a false negative rate of 21%.  Since then, 
multiple randomised control trials (RCT) had proved 
mammography screening is effective in early detection 
of breast cancers and in reducing the mortality range to 
20-32%.
In the 1990s, Computed Radiography (CR) was used as 
a transition technology from analogue output to digital. 
However, the higher radiation dose associated with CR 
systems without significant benefits over diagnostic 
accuracy makes this technology less acceptable. 
Chiarelli et al in her study showed that CR systems 
were significantly less likely to detect cancers by 21% 
compared with film screen mammography. 
In the digital era in the 2000s, although Full Field Digital 
Mammography (FFDM) had a similar overall diagnostic 
accuracy for screening of breast cancers compared with 
film mammography, digital mammography had been 
shown to be more accurate in women under the age of 
50 years, women with radiographically dense breasts 
and premenopausal or perimenopausal women as 
demonstrated in the Digital Mammographic Imaging 
Screening Trial (DMIST). 
Digital Breast Tomosynthesis
Mammogram is the only method of screening for breast 
cancers proven to have mortality benefits by RCT 
as well as a key diagnostic tool for evaluating breast 
symptoms.  Its accuracy is, however, limited by the 
overlapping dense fibroglandular breast tissue.  Small 
breast cancers or cancers having a similar density with 
the normal breast tissue may be obscured in traditional 
2D mammography.  There isare also concerns of false 
positive recalls and unnecessary biopsies from tissue 
superimposition by overlapping tissues that mimic 
pathology in screening mammography.
Digital breast tomosynthesis (3D mammogram) is 
a revolutionary new screening and diagnostic tool 
designed for detecting early breast cancers.  3D 
tomosynthesis data set virtually eliminates detection 
challenges associated with overlapping structures in the 
breast, being the primary drawback of conventional 2D 
analog and digital mammography. In addition, breast 
tomosynthesis increases lesion and margin visibility, 
help in localising lesions in the breast, reduce false 
positive recalls, and increasescancer detection.
Breast tomosynthesis is a form of limited angle 
tomography.  Multiple projection images of the breasts 
are obtained from different angles of the rotating X Ray 
tube at a low radiation dose through the compressed 
breast.  Images are reconstructed into multiple slices 
of 1mm thickness, viewed by trained radiologists 
through a dedicated monitor which is approved 
for tomosynthesis.  Structures in each plane of the 
tomosynthesis slice are more clearly visible without 
the structure noise from overlapping tissues in front or 
behind the plane of interest.  
First and Second Generation 
Digital Breast Tomosynthesis (3D 
Mammogram)
Although tomosynthesis has the advantages of 
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removing overlapping tissues, it is essential for 
radiologists to read the 3D mammogram together 
with a 2D mammogram.  2D mammogram is essential 
in the assessment of side to side symmetry, to assess 
for interval changes, to detect calcifications which are 
usually distributed in different slices on Tomosynthesis, 
and to recognise the distributional aspect of the features. 
In 2011, the U.S. Food and Drug Administration (FDA) 
approved the use of the first tomosynthesis machine 
to do 3D Mammogram for screening and diagnostic 
purposes, given that an additional 2D mammogram 
has to be performed.  Since then, many studies had 
shown that there were marked improvements in 
cancer detection and lower false positive recalls with 
implementation of tomosynthesis compared with 2D 
mammography alone.
Despite the advantages of better cancer detection in 
the first generation tomosynthesis, the technology 
was not widely used as people were concerned about 
the additional 2D mammogram exposure and the 
discomfort associated with the longer compression 
duration.  
Advantages of Second Generation 
Digital Breast Tomosynthesis
With advancements of  technology,  the second 
generation tomosynthesis utilises the 3D dataset to 
synthesise or reconstruct a 2D mammogram image 
without an additional exposure of 2D mammogram. 
Its use was approved by the U.S FDA in late 2013. 
The synthesised 2D Mammogram has image quality 
comparable to a FFDM and has been established in the 
Oslo Screening trial.
Without the need for additional 2D Mammogram 
exposure, the radiation dose used in the second 
generation tomosynthesis can be half of that in the first 
generation and the breast compression duration can be 
shortened.  
By eliminating the overlapping tissues, tomosynthesis 
can assess the lesion margin more accurately (Fig 1) and 
detect better morphological details (Fig 2).  More cancers 
can  be detected be it  in  dense breasts or fatty breasts 
(Fig 3 & 4). It can also eliminate the need for additional 
spot compression views as clarification of false positive 
tissue superimposition and detection of distortion can 
be readily seen by reading through the tomosynthesis 
slices.  There is  no need for additional tangential views 
to establish whether a nodule or calcifications are skin 
lesions by identifying the lesions at the top or bottom 
slices of the set of tomosynthesis images. (Fig 5)  It may 
also offer another benefit of applying less compression 
force in tomosynthesis without compromising image 
quality.
Multiple researches have reported on the clinical 
performance of breast tomosynthesis and found 
increased sensitivity (cancer detection) and specificity 
(reduction in false positive result).  It was also reported 
that tomosyntheis can have a 40% increase in the 
detection of invasive cancers and a 15% drop in the 
recall rate.
Fig 1: Lesion margin assessment is more accurate.  In 2D 
image, the margin is partially obscured by overlapping 
glandular tissue (a).  In tomosynthesis, the overlapping 
tissue is removed, resulting in sharper lesion margin (b).
Fig 2: Spiculations are more obvious in tomosynthesis 
slice.  In 2D image, the mass appears circumscribed (a).  In 
tomosynthesis, it is obvious that it is a spiculated mass. (b)
Fig 3: Right breast cancer can be missed in 2D mammogram.  
The spiculated mass is mammographically occult on 2D 
mammogram (a).  The cancer is obvious in tomosynthesis (b).
Fig 4: Tomosynthesis can identify lesions that can be 
missed in 2D mammogram.  An oval mass is obscured in 2D 
mammogram (a).  The mass is obvious in tomosynthesis 
(b).  Ultrasound shows that it is a non-parallel lesion and 
subsequent biopsy confirms that it is an invasive ductal 
carcinoma (c).
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Fig 5: Tomosynthesis can preclude the use of a tangential 
view.  2D mammogram shows calcifications, without 
knowledge whether they are inside the breast or skin 
calcifications (a).  The calcifications are shown to be at skin 
layer by identifying the calcifications at the top slice of the 
tomosynthesis dataset (b).
In the Screening with Tomosynthesis or Standard 
Mammography (STORM) trial, the cancer detection 
rate  increased from 5.3  per  1000 screens with 
2D mammogram to 8.1 per 1000 screens when 
tomosynthesis was combined with 2D mammography 
and an estimated 17% reduction in recalls.
The first large-scale population-based study in the U.S. 
published in 2013 found that  breast tomosynthesis was 
associated with a significant increase in breast cancer 
detection rates (up 35% for overall cancers and 53% for 
invasive cancers).
A  recent  s tudy  invo lv ing  more  than  450 ,000 
examinations published in 2014 reported that with the 
addition of tomosynthesis there was a 41% increase in 
the detection of invasive breast cancers, a 49% increase 
in positive predictive value (PPV) for recalls and a 21% 
increase in PPV for biopsies.  There was also a 15% 
reduction in recalls.  
Radiation Dose
For the first generation tomosynthesis (3D mammogram 
and additional 2D exposure), the mean glandular 
dose(MGD) for a 5cm thick 50% glandular breast 
is 2.5mGy, which is less than the Mammography 
Quality Standards Act limit for a two view screening 
mammography study. For the second generation 
tomosynthesis, the only exposure is for the 3D dataset 
and the dose is 1.3mGy which is about half of the first 
generation.  Tomosynthesis study, which generates a lot 
more images, can be performed within the range of that 
for standard 2D mammography (1.2mGy).
It has to be stressed that while worrying about the 
radiation dose of tomosynthesis study which gives a 
lot more information from the images, the CR system 
and the older generation film screen mammography 
did have much higher radiation doses compared with 
digital mammography.   As less additional views would 
be required in tomosynthesis, the radiation dose for 
second generation tomosynthesis with synthesised 2D 
mammogram can have much lower levels of radiation 
than a 2D mammogram utilising CR systems or film 
screen mammography with or without additional views. 
Tomosynthesis guided Biopsy
The tomosynthesis technology can be extended to the 
biopsy platformThe target mammographic lesion can be 
visualised clearly on tomosynthesis slices without the 
need for doing stereo-pair images that may sometimes 
be difficult for lesions that can only be seen in one view 
or corresponding targets in stereo-pair images cannot be 
confidently localised, such as in patients with multiple 
scattered and grouped microcalcifications.  This not only 
speeds up the biopsy procedure by easier and accurate 
lesion targeting but also offers biopsy of those lesions 
that are only detected on tomosynthesis. 
Disadvantages of Digital Breast 
Tomosynthesis
The capital cost and maintenance cost are increased, not 
only for the machine but also the need for a dedicated 
workstation approved for tomosynthesis.  It also 
requires a larger storage size for the large amount of 
digital images generated. There is a learning curve for 
radiologists to master images reading and the reading 
time is much increased to as much as 1.5 to 2.3 times 
compared to conventional digital mammography as 
there are  more images required to be read. Moreover 
there are still some limitations in the detection of 
calcifications. Italso requires the provision of a 
tomosynthesis guided biopsy option for patients with 
lesions that are only visible on tomosynthesis.
Digital breast tomosynthesis cannot replace an 
ultrasound study which is a primary imaging modality 
to evaluate a breast mass.  For a mass detected by 
tomosynthesis, there is no way to tell whether it is cystic 
or solid, or the vascularity or stiffness of the lesion 
without a supplementary ultrasound study. 
ACR Statement
In 2014, the American College of Radiology (ACR) 
issued a Statement on Breast Tomosynthesis which 
stated that breast tomosynthesis has been shown to be 
an advanceover digital mammography, with higher 
cancer detection rates and fewer patient recalls for 
additional testing.  Tomosynthesis has been shown to 
improve key screening parameters compared to digital 
mammography.  This technology is now used in clinical 
practice and is no longer investigational.
Conclusion
Digital Breast tomosynthesis (3D mammogram) not 
only has better accuracies in terms of increased cancer 
detections and reduced false positive results, it can also 
be performed more comfortably for women  with fewer 
additional spot compression views and less compression 
can be applied than that in traditional 2D mammograms 
with no evident difference in image quality.  However 
there are still some limitations and hence case selection 
is important. With increased knowledge and experience, 
Digital Breast tomosynthesis is likely to be the future 
standard of care in breast imaging. 
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Introduction
With the increase in public awareness of breast cancer 
and increasing use of breast imaging, there are more 
screen detected and non-palpable breast cancers. 
Surgery remains the mainstay of treatment for breast 
cancer, the goals of which include complete resection of 
the tumour, with negative margins in order to reduce 
the local recurrence and to obtain the pathological 
staging so as to provide the prognosis and subsequent 
adjuvant treatment.  For the primary tumour, there are 
two main types of surgery, namely mastectomy and 
breast conserving therapy.  For the axillary part, either 
sentinel lymph node biopsy or axillary dissection would 
be done.  For mastectomy patients, reconstruction could 
be performed as an immediate procedure or performed 
at a delayed stage.
Pre-operative diagnosis for breast cancer
For breast cancer patients, it is preferable that histological 
confirmation of malignancy is available before definitive 
surgery.  This is usually done by large bore needle core 
biopsy.  In this way, better planning (including need for 
axillary surgery and options of immediate reconstruction) 
can be discussed in detail. In addition, intraoperative 
frozen section confirmation and re-operation can be 
avoided. Pre-operative histological confirmation is 
preferred in addition, as cytology can associate with false 
positive results.  Apart from confirmation of malignancy, 
immunohistochemical staining on large bore needle core 
biopsy specimens also provides information on tumour 
grading, ER and PR status, overexpression for c-erbB2 
oncoprotein and Ki 67 status. This information together 
with the clinical staging, will help to select patients 
who will benefit from neoadjuvant treatment.  Such 
information is also paramount in the decision of post-
operative adjuvant therapy. 
Surgical management of breast cancer 
patients
Surgery involving the primary tumour would either be in 
the form of breast conservation therapy or mastectomy. 
 
For breast conservation therapy, we have to localise 
the tumour before the operation.  Accurate localisation 
will enable achievement of negative margins with the 
minimum excision volume.  There are several ways to 
do the localisation, namely by palpation, ultrasound, 
stereotactic technique by inserting a hook wire or 
injection of isotopes.  In suitable cases, endoscopic 
assisted breast conserving surgery would be done. 
For those non-palpable lesions, prior localisation is 
usually performed by a radiologist on the day of the 
operation.  Intraoperatively, we resect the target lesion 
with the help of a hand held gamma detector probe or 
with the guidance of a hook wire.  The specimen would 
then be sent to the radiology department for specimen 
mammogram and scintigraphy to ascertain that all the 
targets are removed during the operation.
For patients undergoing mastectomy, it is mandatory to 
have a histological confirmation prior to the operation. 
Currently, mastectomy variations include simple 
mastectomy, skin sparing mastectomy, nipple areolar 
sparing mastectomy and areolar sparing mastectomy. 
The choice depends on the size, site of the primary 
tumour, presence of skin involvement and reconstruction 
decisions. Skin sparing mastectomy, nipple areolar 
sparing mastectomy and areolar sparing mastectomy 
are suitable for patients who undergo immediate 
reconstruction. Reconstruction can be performed by 
using autologus myocutaneous flaps, or implants. The 
most common myocutaneous flaps used are the TRAM 
(Transverse rectus abdominis flap) and the latissimus 
dorsi flap. There is also an option of an DIEP flap (deep 
inferior epigastric perforator flap) if plastic surgical 
expertise is available. The prosthesis used is usually 
either a saline or silicone gel prosthesis. For some cases 
where a two staged approach is anticipated, a temporary 
expander of all the above mastectomy and reconstruction 
options, oncological clearance is still the first priority.
The chief aim of axillary procedure is for nodal staging 
which dictates subsequent adjuvant treatment. For 
clinical T1 or 2 N0 tumours, a sentinel lymph node (SLN) 
biopsy is the standard procedure. SLN could either be 
localised by blue dye, isotope or both. The blue dye 
would be injected by the surgeon after anaesthesia while 
the Tc-99m sulphur colloid isotope would be injected by 
a radiologist/nuclear medical specialist at the radiology/
nuclear medicine department. The harvested SLNs would 
be sent immediately to the pathology department for 
frozen section.  If the SLN is positive for metastasis, level 
1 & 2 axillary dissection would be performed in the same 
operation.  Pre-operative counselling would include the 
false negative rate of the frozen section as this is higher 
when the size of the metastasis is smaller than 0.2mm. 
The decision on reoperation should be individualised if 
the paraffin section confirms LN metastases which were 
not diagnosed during frozen section.
Axillary management for ductal carcinoma in situ 
warrants special consideration.  As DCIS is usually 
confined within the breast, level 1 & 2 axillary dissection 
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is not indicated.  However, if the preoperative diagnosis 
is established by core biopsy, there is a chance of under 
diagnosis as invasive foci may be missed by the initial 
biopsy.  Therefore in selected cases (i.e. high grade DCIS, 
mass forming DCIS, patient undergoing mastectomy) 
SLN biopsy is advisable. However, intraoperative 
analysis by frozen section may not change intraoperative 
management decision and therefore can be omitted and 
further planning can be made when final pathology 
results are available.
The surgical management of breast cancers has  evolved 
from more radical resections to a more conservative 
approach both in the breast and axilla. There is also an 
increased use of neoadjuvant therapy and oncoplastic 
surgical techniques which have increased the spectrum of 
women who would be able to choose breast conservation 
surgery as an option. Cosmetic outcomes after oncoplastic 
surgery and reconstructive surgery have increased the 
choice of surgery to achieve cosmetically sound results 
and yet not compromising oncological care.
Follow-up protocol
Follow-ups of breast cancer patients can detect local 
recurrence, systemic metastases, contralateral breast 
cancer and complications from previous treatment 
(e.g. lymphoedema, amenorrhoea, osteoporosis, keloid 
scar…).  Regular full body imagings such as the use of 
CT scan, PET CT scans and tumour marker analysis 
is not considered standard of care at present as their 
use will not prolong survival.  Regular surveillance 
mammogram with options of ultrasonography as 
a compliment is recommended to detect ipsilateral 
breast tumour recurrence and contralateral cancer. 
As recurrence may occur >5 years after completion of 
definitive treatment, breast cancer patients should have 
extended clinical follow-ups.
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A. Lymphoedema Management 
1. Introduction
Lymphoedema is an abnormal accumulation of protein-
rich fluid in the interstitial space caused by obstruction 
of the lymphatic drainage system.  The condition causes 
chronic inflammation and reactive fibrosis of the tissue 
and may progress to elephantiasis.
Breast cancer related lymphoedema (BCRL) is a type 
of secondary lymphoedema complicated by cancer 
treatment such as surgery or radiation therapy, which 
would damage the lymph system. One in five women 
breast cancer patients develops arm lymphoedema. 
Extensiveness of lymph nodes excision, radiation 
therapy, obesity, infection and genetic predisposition 
are the risk factors for BCRL. 
2. Stages of Lymphoedema
The staging of the lymphoedema published by the 
International Society of Lymphology is as follow:
Stage 0: Latent or subclinical
Swelling is not yet evident; impaired lymph transport; 
subtle changes in tissue fluid and/or composition; 
change in subjective symptoms e.g. feeling heaviness
Stage 1: Reversible 
Oedema regresses  wi th  l imb e levat ion ;  ear ly 
accumulation of fluid that is relatively high in protein 
content; pitting oedema may be present
Stage 2: Irreversible
Irreversible oedema with fibrosis, hyperpigmentation
Stage 3: Lymphostatic elephantiasis 
Trophic skin changes; extensive fibrosis may cause 
hardening of tissues and disfigurement, easy infection 
of skin; uncontrolled buildup may develop elephantiasis 
3. Assessment of Lymphoedema by Bio-
impedance measurement 
It is hard to cure lymphoedema. Hence, preliminary 
evidence is to advocate early detection and expedite 
intervention so as to prevent the condition from 
deteriorating. Bio-impedance spectroscopy (BIS) can aid 
early detection and early intervention.
Bio-impedance spectroscopy (BIS)
Bio-impedance is the measurement of tissue 
resistance to an electrical current. BIS is used to 
measure differences of extracellular fluid in an 
arm or leg using the unaffected arm or leg as a 
reference presented as a ratio. The standardised 
cut-off value to demonstrate the presence of 
lymphoedema is determined by the ratio greater 
than a mean ratio plus three standard deviations 
observed in a comparable healthy population. 
The BIS device score (Diagram 1), which indicates 
whether the extracellular fluid is within normal 
range or beyond the ratio threshold, can be an 
early sign of lymphoedema. It aids in detecting 
sub-clinical unilateral lymphoedema Periodic 
monitoring with BIS reduces the incidence of 
clinical lymphoedema from 36.4% to 4.4%.
Diagram 1: (above) a score within normal range; (below) 
a score outside the normal range implying early sign of 
lymphoedema5. 
3.1. When to perform a BIS?
It is advised to do a preoperative baseline 
assessment followed by periodic BIS measurements 
with 3 – 6 months intervals is suggested. . Effective 
prevention of lymphoedema helps to improve 
quality of life and reduces the health care costs.  
3.2. How is a BIS performed? 
Measurements are performed with the patient in 
a supine position. Electrodes are attached to the 
standard anatomical positions (Picture 1) by a 
trained nurse or physiotherapist.
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3.3. Limitations
BIS has limitations in bilateral swelling since 
there is no “normal side” for comparison. In 
such patients, circumference measurements 
would be a better choice for monitoring. The pre 
and post-surgery circumference measurements 
provide affordable, convenient and yet reliable 
information but sub-clinical lymphoedema may be 
undetectable.  
Picture 1: Electrodes placed in standardized anatomical 
position at wrist and ankle 
4. Treatment of Lymphoedema
4.1. Combined Decongestion Therapy (CDT)
CDT is an effective way to manage lymphoedema 
and consists of the following components: 
4.1.1.Manual Lymph Drainage (MLD)
MLD promotes the lymph flow by stretching and 
releasing of the skin. This rhythmic massaging of 
the skin helps to stimulate the lymphatic flow and 
its return to the blood circulation to the desired 
directions of flow. Therefore in unilateral BCRL, 
lymph fluid is redirected from the affected limb and 
axilla to the unaffected axillary lymph nodes and 
ipsilateral side of the inguinal nodes. For bilateral 
BCRL, the lymph fluid of the bilateral axilla will be 
directed to the bilateral inguinal nodes. 
4.1.2. Compression Therapy
Compressive bandaging or compressive garment 
is used. Multilayer bandaging (Picture 2) of the 
upper limb is done such that high pressure is 
applied distally with gradual decrease in pressure 
proximally. Short stretch bandage provides low 
resting pressure while the arm is in a static position 
and provides high pressure when the arm is in 
motion. This enables adequate swelling control at 
rest while increasing effectiveness when muscles 
are contracting. Bandages can also soften fibrosis.
A compressive sleeve is relatively easier to wear 
and therefore more convenient when used in 
daily life. A compression force of 20-30 mmHg is 
suggested. Multilayer bandaging has an advantage 
over commercially-made compressive sleeves 
(Picture 3) as it provides better pressure support 
to the changeable and irregular shape of the arm 
compared to the latter.
Picture 2: Multilayer bandaging 
Picture 3: (above) commercially-made compression sleeve; 
(below) tailor-made flat-knitted compression sleeve and 
glove
Tailor-made flat-knitted pressure garment is also 
recommended as it provides optimal pressure over 
the narrow part of the arm as well as the widest 
part of the arm and hand. 
For lymphoedema stage 0 and 1, a compressive 
sleeve will be used to stabilise the swelling and 
prevent deterioration. For lymphoedema stage 
2 and 3, compressive bandaging will be the 
predominate choice for reducing the volume of the 
swollen arm.
4.1.3. Skin Care
Compressive bandages and garments may absorb 
the moisture and oil of the skin and stress the skin. 
Regular application of a pH-neutral cream can 
maintain hydration of the skin.
4.1.4. Therapeutic exercise and breathing exercise
Muscle and joint movements will increase passive 
lymph transport in intramuscular, intracapsular 
and intraligamentary lymph collectors.
Abdominal breathing changes the intra-abdominal 
pressure which acts as a pump to the deep lymph 
ducts and promotes the lymph flow.
4.2 Treatment phases for CDT
Phase 1   Decongestive phase
This is the intensive treatment phase. A daily 
treatment for 4-6 weeks according to the severity 
of the lymphoedema is recommended. Daily 
MLD and bandaging is applied with instructions 
for exercises. Compression bandage should be 
worn 24 hours if tolerable. There should not be 
any numbness or pain. The aim is to achieve the 
maximum volume reduction and once volume 
reduction has plateaued, phase 1 treatment will be 
weaned off and the patient can be progressed to 
the maintenance phase.
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However, most patients are unable to comply with 
a daily treatment regimen for 4 weeks and for less 
severe cases 2 weeks is acceptable.   
Phase 2   Maintenance Phase 
Patients and their caregivers will be trained with 
self-MLD and bandaging techniques at home 
during phase 1. Tailor-made pressure garment 
is suggested when patients are discharged 
from physiotherapy. The goal of this phase is to 
maintain themselves to what has been achieved in 
Phase 1. (Picture 4)
Patients will be educated on how to handle 
changes in lymphoedema condition and taught 
how to strengthen their arm without making the 
lymphoedema worse. They are guided to modify 
daily life to avoid overstress of the arm. They 
should be confident in self-home management of 
their condition upon discharge.
Picture 4:  (left) before treatment; (right) after treatment 
5.Conclusion
Lymphoedema is a progressive condition if it is 
untreated and can be disabling. Patients should be 
equipped with the knowledge and skills to prevent and 
manage this secondary sequela from cancer treatments. 
Physiotherapists provide pre-operative examinations, 
educations, ongoing monitoring, early identification 
and specialised CDT intervention. Proactive prevention 
and effective management can enhance the life quality 
on their road to recovery.
B. Physical Fitness Training 
1.  Background Information 
Cancer patients very often experience side effects 
that limit their physical ability during treatment and 
afterwards. Overall physical function is generally 
diminished because of loss of aerobic capacity, muscle 
tissue, flexibility, body composition and neuromotor 
function. Exercise is an important treatment for the 
recovery and rehabilitation of cancer survivors.
Cancer-related fatigue is indeed the most common 
symptom in breast and other cancer survivors. It often 
causes significant disruption in functioning and affects 
quality of life. The medical origin such as anaemia, 
cachexia and dehydration should be treated first. If the 
level of fatigue persists with unrelated recent changes 
in activity level, patients are advised to undergo a 
supervised exercise programme for improving physical 
fitness and cognitive behavioural therapy for lifestyle 
adjustment. An early-supervised exercise programme 
can have positive effects on cancer-related fatigue, 
submaximal cardiorespiratory fitness and muscle 
strength.
Supervised exercise also improves overall quality of 
life.  Most breast cancer survivors are overweight obese 
which contributes to a worse prognosis among breast 
cancer patients. Exercise helps to maintain or reduce 
weight.  
Evidence has shown that breast cancer survivors 
have an increased risk of heart failure and coronary 
artery disease, which may be related to chemotherapy 
and radiation induced cardiac toxicity. Exercise 
rehabilitation reduces such risks. 
2. Exercise Testing 
Measurement of physical fitness is a common practice 
in rehabilitative exercise programmes. The test helps 
to provide data in the development of individualised 
exercise regimes, collect baseline and follow-up data for 
evaluation of progress and to establish fitness goals.
There are a few considerations prior to exercise testing 
and designing the exercise programme 
•
•
•
•
•
•
•
•
Evaluation for peripheral neuropathies and 
musculoskeletal morbidities secondary to 
treatment If there has been hormonal therapy 
and/or known metastatic disease to the bone, risk 
of fracture needs to be assessed 
Assessment of likelihood of cardiac toxicity 
Evaluate shoulder morbidity prior to upper body 
exercise 
Evaluate health history, comorbid chronic 
diseases and any exercise contraindications 
Evidence- based literature indicates 1RM testing 
is safe among survivors of breast cancer 
Use a leg ergometer rather than treadmill for 
exercise testing (for overweight and obese 
patients) 
Begin the test at a low initial workload and small 
increments per testing stage (for overweight and 
obese patients) 
No exercise testing is required to start a light 
intensity walking, progressive strength training, 
or flexibility programme 
3. Exercise Programme 
Survivors of cancer should avoid inactivity during and 
after treatment.  Patients should return to normal daily 
activities as quickly as possible after surgery. 
The exercise programme recommended by ACSM is as 
illustrated: 1:
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Type Aerobic training, resistance and flexibility exercise 
Frequency Aerobic:  3 – 5 days per week and gradually increase to ≥5 
days per week to maximise caloric expenditure 
Resistance: 2 – 3 days per week 
Flexibility: Daily 
Intensity • Exercise tolerance may be highly variable during active 
treatment. Survivors who have completed treatment may 
increase intensity slowly for all physical activities. 
• Heart rate may be less reliable for monitoring intensity 
for cancer survivors. Therefore, it is advised to use self-
rated perceived exertion (RPE) instead. However, heart 
rate reserve (HRR) method is potentially the most feasible 
method for clinical use4. Therefore, both methods would 
be taken into consideration. 
• If the patient is able to tolerate the exercise without 
adverse effects, the exercise intensity needs not differ from 
healthy populations: 
Aerobic: moderate intensity (40% - < 60% HRR/ VO2R, RPE 
12- 13 / 20) and eventual progression to vigorous intensity  
(60% - 80% HRR/ VO2, RPE 12 – 16/ 20) 
Resistance: Start with a very low resistance, progress 
resistance at small increments. No upper limit on the 
amount of weight to which survivors can progress. Watch 
for any lymphoedema symptoms and change accordingly.
Flexibility: To the point of tightness or slight discomfort. 
Not to exceed ROM restrictions resultant to surgery and/or 
radiation therapy. 
Time Aerobic: A minimum of 30 minutes per day progressing to 
60 minutes per day
Accumulation of intermittent exercise of at least 10 minutes 
short bouts is an effective alternative to continuous exercise 
at the beginning 
Resistance: At least 1 set of 8 – 12 reps
Flexibility: 10 – 30 seconds hold of a static stretch for 2 – 4 
reps (a total of 60s per joint is recommended) 
Progression Slow progression for cancer survivors. If the exercise 
leads to an increase in fatigue or other common adverse 
symptoms, the programme should be reduced to a level 
that is better tolerated. 
Changes in arm/shoulder symptoms or swelling should 
result in reductions or avoidance of upper body exercise 
until after appropriate medical evaluation and treatment. 
4. Conclusion
Every individual with cancer can have a unique 
experience and response. Therefore, whilst using 
standard guidelines, we should implement our clinical 
judgements to provide a suitable fitness training 
programme for breast cancer survivors. 
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In Hong Kong, breast cancer is the most prevalent 
female cancer with an incidence of more than 3500 
new cases diagnosed every year1. According to the 
American Joint Committee on Cancer staging system, 
breast cancers can be categorised into one of the 4 stages 
(I to IV) based on the size of the tumour, involvement 
of lymph nodes, and spread of tumour outside of 
the breast (a term called metastasis). Without distant 
metastases, most breast cancers are potentially curable. 
The primary treatment modality for early breast cancers 
is surgical excision with mastectomy (removal of the 
whole breast) or lumpectomy (removal of the tumour 
plus surrounding tissue). The addition of adjuvant 
therapy has been proven to significantly enhance long-
term survival after surgery2.
Adjuvant therapy
Even in the early stage, a small amount of cancer cells 
might break away and be carried to distant sites. They 
are not detectable by imaging but could become the 
potential source of recurrence in the future. Adjuvant 
therapy is the treatment given after surgery to decrease 
recurrence and to improve long-term survival. 
Commonly used modalities include systemic therapies 
such as chemotherapy, targeted therapy, or hormonal 
therapy, and localised treatment with radiation therapy. 
Chemotherapy
Chemotherapy is well recognised to decrease tumour 
recurrence. Commonly used regimens nowadays 
include anthracycline, which is often combined with 
cyclophosphamide with or without fluorouracil. In 
the long run anthracycline-based chemotherapy could 
effectively decrease mortality by 20-38%2. For more 
advanced node-positive disease, additional taxane is 
often given for its extra survival benefit3,4. 
These treatments are administered by intravenous 
infusion in cycles, and delivered as an outpatient. 
Depending on regimens, adjuvant chemotherapy 
usually lasts for 4-6 months. Most patients tolerate 
treatment with supportive medication and complete all 
cycles. Although anthracycline can cause more nausea 
and vomiting, these symptoms are fairly well controlled 
with effective anti-nausea medication in the modern 
days. Hair loss is common but it is transient. Treatment-
specific toxicities include anthracycline-induced cardiac 
problems and potential secondary cancer, and taxane-
induced peripheral neuropathy. With combination 
chemotherapy, the chances of bone marrow suppression 
leading to compromised immunity is high so patients 
need to be vigilant about their increased risk of 
infection. Since chemotherapy can permanently damage 
the function of the ovaries, many women develop 
menopause after chemotherapy and issues of family 
planning need to be addressed especially if the patient 
has not completed a family.
Who should receive adjuvant chemotherapy?
Although adjuvant chemotherapy is commonly used, it 
is associated with undesirable side effects. All tumours 
are different, and the benefit of chemotherapy depends 
on the inherent risk of recurrence. In general, the 
higher the stage of a tumour, the higher the risk for 
recurrence and there would be more benefit of using 
adjuvant chemotherapy.  Besides staging, a number 
of tumour factors can also help determine the use of 
adjuvant chemotherapy. For instance, a tumour with 
high proliferative capacity tends to respond better to 
chemotherapy. Younger patients whose tumours are 
often more aggressive and might have more survival 
benefit from chemotherapy. Tumours carrying hormone 
receptors or HER2 receptors behave differently and 
the prognosis can be affected by adjuvant hormonal 
therapy or targeted therapy as well. Diagnostic tests 
such as MammaPrint® or Oncotype DX® are useful 
tools using additional information of gene signatures 
to predict the risk of recurrence when the use of 
chemotherapy is doubtful5,6. These can help identify 
patients who could be spared from chemotherapy and 
the associated side effects.
Hormonal therapy
Some breast tumours carry oestrogen or progesterone 
receptors. Female hormones can trigger these hormonal 
receptors and stimulate tumour growth. Adjuvant 
hormonal therapy is taken everyday orally, and is an 
effective means to decrease recurrence of these tumours. 
Tamoxifen is a commonly used hormonal therapy. It 
antagonises the action of oestrogen, and can be given 
to both pre- and post-menopausal women. Five years 
of adjuvant tamoxifen can significant lower the risk of 
recurrence and death from breast cancer by more than 
30%7. The benefit can be further increased when the use 
is extended to 10 years8. However, prolonged use of 
tamoxifen can increase the chances in blockage of blood 
vessels (a term called thromboembolic events) and 
endometrial cancer. The metabolism of this drug can 
also be interfered by a class of psychiatric medication 
called selective serotonin receptors inhibitors, which 
are used for management of depression and peri-
menopausal symptoms. 
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Post-menopausal women have another choice of 
hormonal therapy. Aromatase is an enzyme that converts 
other hormones into oestrogen. Aromatase inhibitors 
(AI) decrease the residual oestrogen levels, further 
lower hormonal stimulation of the tumour and decrease 
death from breast cancer9.  Among AIs are anastrozole, 
letrozole, and exemestane. Women can take AI for 5 
years, or start with tamoxifen then switch to AI after 
2 years for a total treatment duration of 5 years. Most 
women tolerate the drug well for the whole duration 
of adjuvant treatment. The more common side effects 
are joint pain, muscle pain, and menopausal symptoms 
such as hot flashes and night sweats. Since the drug can 
lead to osteoporosis, preventive measures such as use 
of bisphosphonates or denosumab might be needed to 
improve bone health and prevent premature fracture. All 
women on AI should maintain a good habit of regular 
exercise to strengthen bone density and take adequate 
amounts of calcium and vitamin D in their diet. 
Targeted therapy
About 25-30% of breast cancers express a surface 
receptor called HER2. Activation of these receptors 
triggers tumour cell  growth and we now have 
medication that targets HER2 to turn off the growth 
signal. Trastuzumab (Herceptin®) is the first drug of 
its class. This drug has a selective action on tumour 
cells and has minimal adverse effects on normal 
tissue.  For women with HER2-positive breast cancer, 
addition of the adjuvant trastuzumab to chemotherapy 
decreases the risk of recurrence by 50% compared 
with chemotherapy alone10,11. This drug is given 
intravenously usually every 3 weeks, for a total of 1 year 
after primary surgery. Although this drug is very well 
tolerated, about 5% of patients develop heart failure so 
patients on this drug should have regular monitoring 
of heart function by 2-dimensional echocardiography 
or radionuclide ventriculography. This cardiotoxicity 
usually improves once the drug is stopped12.  
Radiotherapy (RT)
Adjuvant RT given after surgery has been shown to 
reduce the incidence of locoregional recurrence and 
breast cancer deaths13-14. It is an integral part of breast-
conserving therapy (BCT), which has become the 
most acceptable standard of care for the majority of 
women with early stage invasive breast cancer with 
the advantage of achieving the most optimal cosmetic 
results. For patients with mastectomy performed, 
adjuvant RT is recommended for patients with large 
tumour size or lymph node metastases15. Traditionally, 
RT is given as a daily treatment, 5 days a week over 
5 weeks to deliver 50Gy in 25 fractions. Modern 
hypofractionated RT schemes using fewer treatments 
(13-15 fractions) and shorter overall treatment time (2.5-
3 weeks) can achieve equivalent treatment outcome and 
are more convenient to our patients so that they can 
resume their usual daily activities earlier16-18. Thanks to 
the advances in technology, it is increasingly common 
to use more sophisticated techniques including 3D 
conformal RT (3DCRT) or intensity-modulated RT 
(IMRT) to deliver adjuvant RT for breast cancer19-20. 
These rapidly evolving techniques make it possible to 
direct the radiation more accurately to the breast/chest 
wall and the regional lymphatics including the axilla 
and the internal mammary chain. The radiation dose to 
the surrounding normal structures especially the heart 
and the lungs can be markedly reduced (Figure 1) and 
thus long term side effects can be minimised.
Figure 1. RT to the left breast using advanced RT technique. 
The left breast receives a high radiation dose while the 
heart is well protected.
Neoadjuvant therapy
Sometimes a breast cancer grows to a size too big to 
be removed surgically, or it is fairly big relative to the 
normal breast tissue so breast conservative therapy is 
not possible. Upfront systemic therapy, a term called 
neoadjuvant therapy, can be used to shrink the tumour 
so it becomes operable or makes breast conservative 
therapy possible.  Neoadjuvant therapy can be 
combination chemotherapy, targeted therapy, or even 
hormonal therapy. In certain institutions the waiting 
time for surgery can be long, neoadjuvant therapy has 
an added benefit of avoiding any delay in treatment. 
Neoadjuvant therapy also has the advantage of assessing 
the response to treatment directly. For certain subtypes 
of breast cancer, a complete clearance of the tumour by 
treatment at the time of surgery (pathological complete 
response (pCR)) is linked to better long-term survival 
outcome. This characteristic has made neoadjuvant 
therapy an attractive platform for evaluation of novel 
drug regimens. For instance, pertuzumab is a new drug 
targeting HER2 receptors. Addition of pertuzumab 
to the existing regimen of trastuzumab and docetaxel 
boosted the rate of pCR from 21 to 39%21. As a result of 
this study, the drug was granted accelerated approval 
by the U.S. Food and Drug Administration for use in 
the neoadjuvant setting. The practice of neoadjuvant 
therapy requires close collaboration between oncologists 
and surgeons and therefore it is usually adopted in 
more established units. 
Summary
Early breast cancer is a potentially curable disease. 
Multiple modalities are available to improve the long-
term outcome by cutting down tumour recurrence. 
Chemotherapy, hormonal therapy, targeted therapy, 
and radiotherapy can be the integrated parts of 
treatment.  Even for locally advanced tumours that 
are not amenable for primary surgical resection, 
neoadjuvant therapy can help shrink the tumour and 
makes surgery possible. Treatment for breast cancer is 
a rapidly growing field and we are looking forward to 
more effective therapies with less toxicity.
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Introduction
Despite improvements in adjuvant treatment for 
early-stage breast cancer, up to 25-30% patients will 
still develop recurrences and metastases. Moreover, 
around 5-10% breast cancer patients are found to have 
metastatic diseases at presentation. Although metastatic 
breast cancer (MBC) is a highly treatable disease, it is 
still generally incurable. New targeted therapy agents, 
chemotherapeutic drugs and hormonal agents have 
been developed in recent years but the progress is 
relatively slow and the median overall survival is still 
only 2-3 years. It should be noted that the range is wide 
in this highly heterogeneous group and up to 30% may 
survive for 5 years. 
The goals of treatment are to lengthen the survival, 
minimise the associated symptoms and hence improve 
their quality of life (QOL). The balance between 
treatment benefits and toxicities is most important. With 
the escalating cost of new cancer treatment, funding 
and resources are increasingly the prime concern in the 
choice of therapies.     
General Principles
In view of the great variations of disease status in 
advanced breast cancers, a multidisciplinary and 
individualised approach is critical. The patients should 
be included in all steps of the decision-making process 
and their preferences should be duly respected. The 
treatment strategy should be tailored according 
to individual priorities and disease status with 
consideration of their physical, functional, psycho-social 
and spiritual needs. 
Although occasional patients with isolated secondary 
or oligometastases may benefit from aggressive local 
ablative therapies and achieve complete remissions and 
long survivals, metastatic breast cancer is essentially a 
systemic disease that requires systemic treatment. 
There are three main systemic inventions: hormone 
therapy, chemotherapy and biologic agents (especially 
anti-HER-2 agents). These can be used sequentially or 
concurrently in various scenarios. There are different 
breast cancer subtypes, clinically classified according 
to their ER (Oestrogen Receptor), PR (Progesterone 
Receptor) and HER-2 (Human Epidermal Receptor 2) 
status (Figure 1); hormonal therapies and anti-HER2 
therapies are only relevant to tumours having respective 
positive receptor tests in the immunohistochemical tests. 
Figure 1. Clinical breast cancer subtypes, classified 
according to commonly available immunohistochemical 
tests. Hormone receptor (HR) is considered positive if ER 
(Estrogen Receptor) and/or PR (Progesterone Receptor) is 
positive.
Assessment Principles
Apart from a complete history and physical examination, 
the initial assessment should also include blood tests 
to evaluate basic organ functions and preferably 
serum tumour markers (e.g. CA15.3 and CEA), to 
facilitate disease monitoring, if elevated. PET-CT scans 
are increasingly used to replace the traditional CT 
imaging (of thorax and abdomen) and bone scan due 
to their increasing availability and higher sensitivity. 
However, a routine brain imaging (e.g. MRI brain) to 
exclude brain metastases in asymptomatic patients is 
not recommended. Evaluation of response to therapy 
is crucial and the imaging studies (of evaluable sites) 
should be done every 2-4 months; however, less frequent 
monitoring is acceptable for more indolent disease.  
As the biological markers profile (ER, PR, HER2) may 
evolve in a small percentage of patients, repeating a core 
biopsy at the metastatic site, if clinically feasible, should 
be considered. If the tumour biology in the metastatic site 
differs from the original primary tumour, however, it is 
unclear which biological profile should guide the choice 
of treatment. It is generally recommended to consider the 
use of targeted therapy (hormone therapy and/or anti-
HER-2 agents) when receptors are positive in at least one 
biopsy, regardless of timing1.          
Various factors affecting the choice of treatment are listed 
in Table 1. It should be emphasised that the age of the 
patient should not be the sole reason to withhold effective 
therapy in elderly patients nor to overtreat in young 
patients.1 
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Table 1 Factors affecting treatment choice in Metastatic 
Breast Cancer (MBC)
Disease-related factors Patient-related factors
Biological markers: ER/PR/
HER-2 status
Biological age
Previous therapies : 
response and toxicities
Performance status
Disease-free interval Co-morbidities (including organ 
dysfunction)
Tumour burden (number 
and site of metastases)
Menopausal status (for hormone 
therapy)
Need for rapid disease/
symptom control
Psychological and socioeconomic 
factors (particularly funding 
constraint)
Patient preference
Systemic Treatment
A. Hormone therapy 
For patients with hormone receptor (ER and/or 
PR)-positive metastatic breast cancers, hormone 
therapy is the initial systemic treatment of choice 
unless there are life-threatening components (e.g. 
massive liver metastases), systemic symptoms 
requiring immediate palliation (e.g. shortness of 
breath due to lymphangitis carcinomatosis of lung) 
or concerns about endocrine resistance (e.g. only 
weakly positive hormone receptors)2. Contrary to 
traditional belief, visceral involvement alone is not 
an indication for chemotherapy and patients with 
a limited visceral component can be safely treated 
with hormone therapy.. The benefit of second-line 
hormone manipulation can be up to 50% in relapsed 
disease and failure to benefit from an initial trial with 
hormone therapy correlates with subsequent failure. 
Common hormone agents are listed in Table 2. 
Table 2 Common hormone agents 
Hormone Agent Dose and schedule Suitability
Tamoxifen 20mg PO daily Pre- and post-
menopausal
Aromatase 
Inhibitors: 
Anastrozole
Letrozole
Exemestane
1mg PO daily
2.5mg PO daily
25mg PO daily
Post-menopausal
Fulvestrant 500mg IM monthly Post-menopausal
Lutelinising 
hormone-releasing 
hormone (LHRH) 
analogue: 
Goserelin
Leuprolide
3.6mg SC monthly
7.5mg IM monthly
Premenopausal
Alternatives include 
ovarian ablation by 
oophorectomy or 
radiotherapy 
For premenopausal patients, ovarian suppression/
ablation combined with additional hormone 
agents like tamoxifen or an aromatase inhibitor 
is often preferred. Ovarian suppression can be 
achieved through ovarian irradiation, LHRH 
analogues injection or surgical oophorectomy.
The preferred first-line hormone therapy for 
postmenopausal women depends the adjuvant 
hormone therapy regime.  Options  include 
aromatase inhibitors, tamoxifen or fulvestrant. 
For metastatic postmenopausal patients without 
prior use of any aromatase inhibitor, an aromatase 
inhibitor is often the first choice due to its lower 
cost, convenience of use (compared with fulvestrant) 
and higher efficacy (compared with tamoxifen).
 
It should be noted that the original fulvestrant 
dose is 250mg IMI monthly at its introduction and 
it has been demonstrated to have similar efficacy 
as aromatase inhibitors. However, a subsequent 
study showed that the higher dose fulvestrant 
(500mg IMI monthly) was equally well tolerated 
but would achieve a 4 month longer median overall 
survival. So far there are no data directly comparing 
fulvestrant 500mg with an aromatase inhibitor. To 
further complicate the issue, a recent randomised 
study found that the combination of anastrozole (an 
aromatase inhibitor) and fulvestrant was superior 
to anastrozole alone or sequential anastrozole and 
fulvestrant, despite the use of a dose of fulvestrant 
(250mg) that was below the current standard.3  
For  MBC pat ients  a f ter  successful  control  by 
chemotherapy, hormone therapy is also often used as 
maintenance to prevent disease progression. However, 
concurrent use of chemotherapy and hormone therapy 
has not shown a survival benefit and hence should be 
avoided outside trial settings.
There are also two new biologic agents to enhance the 
effects of aromatase inhibitors in MBC: everlolimus 
and palbociclib. Everolimus, an oral drug inhibiting the 
mTOR pathway, can be added to steroidal aromatase 
inhibitors to prolong the disease-free survival by 5 
months after failure of a non-steroidal aromatase 
inhibitor.4 Palbociclib is a selective inhibitor of the 
cyclin-dependent kinases CDK4 and CDK6. Its approval 
for use was based on the results of a phase II study in 
which progression-free survival for patients receiving 
palbociclib and letrozole was 20.2 months, versus 10,2 
months for those on letrozole alone. The decision to add 
these biologic agents should take into account of their 
very high cost and toxicities (particularly stomatitis by 
everolimus and neutropenia by palbociclib).   
B. Chemotherapy
Chemotherapy is often needed for rapid disease 
control and may be the only available option 
for patients with negative hormone receptors or 
endocrine resistance. Combination chemotherapy 
gives a higher response rate and earlier onset 
of clinical benefit than a single agent; it may be 
preferred in patients with relatively fit physical 
conditions and life-threatening disease. However, in 
most other scenarios, sequential use of a single agent 
is often preferred so as to minimise the treatment 
side effects, but without jeopardising the survival. 
Anthracycline- or taxane-based regimens are 
popular effective first-line regimens Re-challenging 
with anthacyclines after adjuvant treatment is often 
difficult due to its cumulative cardiac toxicity. 
However, if given in the adjuvant setting, a taxane 
can be re-used, especially if the disease-free 
interval is at least 1 year. Other effective options 
include capecitabine, vinorelbine, carboplatin, 
gemcitabine and newer agents like albumin-
bound paclitaxel and eribulin. As an oral agent, 
the use of capecitabine is particularly attractive; it 
is well tolerated with minimal hair loss and only 
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results in mild marrow suppression. The duration 
of chemotherapy should be tailored to individual 
patients; it is usually around 6 months but can be 
continued till disease progression for agents. 
Whils t  chemotherapy  should  not  be  used 
concurrently with hormone agents, it can be 
combined with a targeted agent like anti-HER-2 
agents (see below) or bevacizumab, a monoclonal 
antibody that blocks tumour angiogenesis by 
inhibiting vascular endothelial growth factor A. In 
contrast to the strong beneficial effect of anti-HER-2 
agents, addition of bevacizumab to first or second-
line chemotherapy for MBC provides only a modest 
progression-free survival benefit but no overall 
survival benefit. Considering the lack of predictive 
test, high cost and potential side effects, its use in 
MBC is controversial. 
C. Anti-HER-2 Agents 
Around 20% of breast cancers have over-expression 
of  HER-2 receptors (Human Epidermal Receptor 
2) and these are more aggressive disease with a 
higher risk of relapse and poorer survival. These 
anti-HER-2 agents are best used together with 
chemotherapy but for patients going to receive 
hormone therapy instead, the addition of anti-
HER-2 agents can also give substantial progression-
free survival benefit. Following the success of 
trastuzumab (a monoclonal antibody that binds to 
the HER-2 receptor) in both adjuvant and metastatic 
settings, other anti-HER-2 agents with different 
mechanisms have been approved for use in the 
metastatic setting. These include lapatinib (an 
oral tyrosine kinase inhibitor which interrupts the 
HER2-2 pathway) and pertuzumab (a monoclonal 
antibody inhibiting the dimerisation of HER2 
with other HER receptors). In first-line metastatic 
settings, however, the combination of chemotherapy 
plus trastuzumab has been shown to be superior 
to chemotherapy plus lapatinib. For previously 
untreated HER-2 positive MBC, the addition of 
pertuzumab to trastuzumab (i.e. dual anti-HER-2 
blockade) to chemotherapy (docetaxel), as compared 
with the addition of placebo, significantly improved 
the median overall survival to 56.5 months.5
T-DM1 (trastuzumab emtansine) is a new class of 
drugs called antibody-drug conjugates. This class of 
drugs combines an antibody, which is able to target 
certain tumour cells, with a cytotoxic agent. By 
delivering chemotherapy through targeted means, 
the cytotoxicity is confined to the tumour cells while 
sparing surrounding healthy tissues. Following a 
failure of trastuzumab-based chemotherapy, T-DM1 
has been shown to provide superior efficacy than 
other combinations.6 
Special Issues 
Surgery of the primary tumour for patients with 
metastases at diagnosis
The true value of the surgical removal of the primary 
tumour in these patients is currently unknown and the 
studies are largely retrospective and conflicting. The 
general consensus is that surgery of the primary should 
not be offered as a routine practice but can be discussed 
on a case-by-case basis and offered to selected patients.
Oligometastatic breast cancer
A distinctive subset of MBC is oligometastatic breast 
cancer, characterised by a single/few detectable 
metastatic lesions. Available data report favourable 
outcomes after ‘radical' local therapy (e.g. surgical 
resection, stereotactic body radiotherapy), in addition 
to systemic therapy, for limited metastatic disease. 
However, selection bias and the retrospective nature of 
data do not allow for generalisation of the results: the 
use of such approaches must be individualised.
Bone Metastases
Up to 70% MBC patients may develop bone metastases 
in their disease courses and it can markedly impair 
the quality of life by causing pain, pathological 
fractures and even spinal cord compression. Apart 
from titration of analgesics, palliative radiotherapy to 
symptomatic or strategic sites should be considered for 
pain relief and prevention of skeletal complications. 
Surgical stabilisation/fixation may also be needed for 
impending fractures of long bones. In cases of spinal 
cord compression, urgent surgical decompression can 
relieve neurological deficits in selected patients with 
limited vertebral level involvement. Apart from systemic 
therapy, a bone modifying agent like bisphosphonates 
(e.g. zoledronic acid) or a RANK-ligand inhibitor (e.g. 
denosumab) is now widely used to prevent skeletal-
related events in patients with bone metastases. 
Denosumab is increasingly popular because of its ease 
of use (monthly subcutaneous injections) and higher 
efficacy; there is also no need for dose adjustment for 
renal impairment as in the case of zoledronic acid. 
Patients receiving these bone-directed therapies should 
be reminded to avoid invasive dental procedures to 
prevent the uncommon occurrence of osteonecrosis of 
jaw and receive calcium and vitamin D supplementation 
to prevent drug-induced hypocalcaemia, which can be 
fatal in rare cases.  
Brain Metastases
Patients with extensive brain secondaries should be 
treated with whole brain irradiation but patients with 1-3 
small brain secondaries may be treated with surgery or 
radiosurgery, with or without whole brain irradiation. 
A recently reported phase III trial (consisting mostly of 
lung cancer participants) found that adding whole-brain 
radiation therapy to radiosurgery did not significantly 
extend survival of patients, although it did help to 
control the growth of brain metastases. The risk of 
cognitive decline versus a longer duration of intracranial 
disease control after whole brain irradiation should be 
discussed with the patient.7
Conclusions
Metastatic breast cancer is a complex and heterogeneous 
disease which remains virtually incurable in nearly 
all patients. Proper choice and sequencing of systemic 
therapies  and other  support ive measures  l ike 
radiotherapy and surgical intervention are crucial to 
lengthen the survival and maintain quality of life. Many 
questions remain unanswered and an individualised 
treatment tailoring to the patient’s needs, psycho-social 
status and funding limitation is important. 
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I. PALLIATIVE CARE & ITS 
INTEGRATION INTO CANCER CARE
Palliative care is a branch of medicine with the goal of 
preventing and relieving pain and suffering.  According 
to WHO1, palliative care:
▪ “provides relief from pain and other distressing 
symptoms”;
▪ “affirms life and regards dying as a normal process”; 
▪ “intends neither to hasten or postpone death”; 
▪ “integrates the psychological and spiritual aspects of 
patient care”; 
▪ “offers a support system to help patients live as 
actively as possible until death”; 
▪ “offers a support system to help the family to 
cope during the patients’ illness and in their own 
bereavement”; 
▪ “uses a team approach to address the needs of 
patients and their families, including bereavement 
counselling, if indicated”; 
▪ “will enhance quality of life, and may also positively 
influence the course of illness”;
▪ “is applicable early in the course of illness, in 
conjunction with other therapies that are intended 
to prolong life, such as chemotherapy or radiation 
therapy, and includes those investigations needed 
to better understand and manage distressing clinical 
complications”.
There is always a role for palliative care at all stages of 
cancer diseases to reduce and control the symptoms 
of cancer and side effects of treatment throughout the 
cancer journey. It is now widely acknowledged that a 
palliative and supportive care approach to care should 
not be utilised only at the end of life, but whenever 
needs are identified irrespective of the stage of the 
cancer2-7. In this regard, The American Society of 
Clinical Oncology (ASCO)8 and The European Society of 
Medical Oncology (ESMO)9,10 recommended palliative 
care be offered along with treatment for patients with 
metastatic cancer and those who have many or severe 
symptoms.  The physical, psychological and social needs 
of cancer patients are addressed by the cooperation 
of a multidisciplinary professional team including 
oncologists, physicians with expertise in palliative care, 
nurses, allied health care providers, home care services, 
social workers, chaplains and mental health care 
professionals.  Palliative care may be offered at home, in 
a hospital or in a hospice.  
Seven randomised controlled trials (RCTs) have 
demonstrated that early integration of palliative care 
into the standard cancer care in patients with advanced 
cancer maintains or improves survival and improves 
quality of life8.
II. METASTATIC BREAST CANCER 
REQUIRES MORE THAN A MEDICAL 
APPROACH
According to the Hong Kong cancer registry 2012, about 
6% of new breast cancers are metastatic when they are 
diagnosed11.  It is expected that around 30% of women 
who are first diagnosed with early stage breast cancer 
will go on to develop metastatic breast cancer12. The 
primary goals of managing advanced breast cancer are 
to improve the length and quality of life. Treatment 
choices are dependent on the balance between the 
potential benefits and side effects of the therapeutic 
options.  Although metastatic breast cancer is considered 
incurable, advances in oncological intervention e.g. novel 
chemotherapeutic and targeted therapies have provided 
more than ever treatment options. The disease could be 
controlled for extended periods of time and allows people 
to live with a good quality of life, and on occasions for 
many years12-17. Despite breast cancer patients can have a 
chance to live for years on stable medical regimens, it is 
inevitable that disease would get out of control and the 
treatment course would become arduous. The experience 
of profound life threat and the accompanying uncertainty 
become the common psychological denominator for both 
the affected woman and her loved ones. The challenges 
of maintaining life balance, as well as managing pain, 
fatigue, and other physical and psychological symptoms 
associated with the disease and treatments reflect the 
consensus that palliative and supportive care are essential 
from the point of diagnosis18,19. Living with metastatic 
breast cancer requires more than a medical approach.
Effects of Metastatic Breast Cancer on 
Quality of Life
Quality of life is a multidimensional construct that 
includes several domains of a person’s life: physical 
functioning,  psychological  functioning,  social 
functioning, sexual functioning and spiritual and 
existential matters20,21. Breast cancers can have significant 
impacts on these domains (see table 1).  The assessment 
of women’s needs for information and support in each 
of these major life domains, and how the needs could be 
met by existing clinical services are very important.
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III. THE PALLIATIVE CARE MODEL 
IN HONG KONG
Integrating Palliative Medicine and 
Oncology in Clinical Service34
Picture 1: Hong Kong East Cluster Pamela Youde Nethersole 
Eastern Hospital Hospice Centre
The public sector is responsible for the majority of 
oncology and palliative care services in Hong Kong. There 
are six oncology centres in Hong Kong, offering clinical 
oncological service (both medical & radiation oncology) 
and palliative care. In 2007, with the support from 
charity funding, day hospice centres were established 
in all six oncology centres. A more comprehensive 
structure of palliative care supporting in-patient care, 
out-patient clinics, ambulatory and home hospice was 
then developed which was never before. The palliative 
service is led and coordinated by clinical oncologists 
who have obtained dual specialist qualifications of 
clinical oncology and palliative medicine from the 
training by the Hong Kong College of Radiologists. 
Palliative service is delivered in a multidisciplinary team 
approach addressing the needs of patients and their 
families, including bereavement counselling. In this way, 
oncological and palliative cares are provided in a one-
stop service with an early introduction and access to 
palliative care.  This approach is advocated by the ESMO 
Programme of Designated Centre of Integrated Oncology 
and Palliative Care10. Three oncology centres in Hong 
Kong have been accredited as ESMO Designated Centre 
under the programme.
Table 1 Impact of metastatic breast cancer on different 
domains of quality of life
Physical Issues: ▪ Physical symptoms related to the cancer and 
treatments e.g. pain, malaise, nausea, vomiting, 
anorexia,  dyspnoea,  abdominal bloating, 
lymphedema, tumour fungation, bleeding etc. 
Doctors should be alert to the symptoms & signs 
associated with the cancer induced conditions 
that require early/urgent treatment (see table 2).
▪ L o s s / d i s r u p t i o n  o f  r o u t i n e  f u n c t i o n a l 
performance & social roles e.g. self-care activities 
(feeding, dressing), mobility (move indoors/
outdoors), physical activities (walking, lifting) 
and personal roles (household activities, work).
Psychosocial 
Issues:
▪ 25-50 % women would experience clinically 
significant anxiety & depression with breast 
cancer recurrence22-23.
▪ Distress level increases as the cancer progresses, 
hence the more pronounced unmet needs in 
terms of psychological support24.
Social Issues: ▪ Negative impact on marital and other relationships 
with family and friends25-28.
- Women may feel their partners could not 
appreciate & understand the devastating 
impact of disease progression.
- F a m i l y  m e m b e r s  m a y  b e  e ve n  m o r e 
distressed than the woman.
- Functional role impairment (see above) 
can restrict the ability to pursue normal 
social activities, limit the social contacts and 
interactions.
▪ Family & social support play critical roles on 
how the women can cope with the disease29. 
More open communication, cohesion, conflict 
resolution and expression of feelings are helpful 
in disease adjustment.
Sexual Issues: ▪ This has not been extensively researched with few 
descriptions in literature30,31.  Elements affecting 
sexuality could be involved:
- Fear of e.g. death, disfigurement, loss of 
partner, being a burden to loved ones.
- Side effects of systemic treatment e.g. hair 
loss, nausea & vomiting, ovarian failure, 
fatigue and general loss of well-being.
Other Issues: ▪ Studies found that existential issues e.g. death, 
freedom, isolation and question of meaning are 
more important among people with advanced 
cancers32, 33.
Table 2 Cancer induced conditions that require early/urgent 
treatment
Diagnosis Symptoms & Signs
Spinal Cord 
Compression
▪ unresolved back or neck pain, 
▪ decreased in feeling or power in arms/legs,
▪ loss of bladder/bowel control
Superior 
Vena Cava 
Compression
▪ dyspnoea, 
▪ arm/facial swelling
Brain metastasies ▪ headache,
▪ nausea,
▪ confusion,
▪ seizures,
▪ personality changes
Hypercalcaemia ▪ confusion,
▪ excessive thirst,
▪ vomiting,
▪ constipation,
▪ increased bone pain
Pulmonary 
Embolism
▪ dyspnoea
▪ tachyarrythmia,
▪ chest pain, 
▪ cough,
▪ leg swelling
Sepsis ▪ fever,
▪ hypotension
Pleural effusion ▪ dyspnoea,
▪ chest pain,
▪ dry cough
Pericardial 
effusion
▪ dyspnoea,
▪ chest pain,
▪ oedema
Liver metastases ▪ jaundice,
▪ nausea,
▪ right upper quadrant pain,
▪ hepatomegaly
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Apart from clinical oncologists,  palliative care 
specialists under the Hong Kong College of Physicians 
are also offering palliative care service in Hong Kong. 
Their service is more focused on the palliative care at 
the terminal phase of life. The scope of service is more 
extensive nowadays. The scope has expanded to cover 
the terminal non-malignant diseases in addition to 
cancers.  
The collaborative model between palliative care teams 
of clinical oncologists and internal medicine physicians 
secured a continual and seamless transition of palliative 
care from active oncological treatment to end-of-life 
care.  It expanded the access to palliative care service 
under the restraint of resource capacity. It may also 
mitigate the fear of being abandoned that some patients 
feel when referred to a palliative care service at the 
terminal stage of illness.
IV. SUMMARY
Metastatic breast cancers influence all aspects of the 
women’s lives. With the advent of more options of 
oncological intervention e.g. targeted therapies and 
supportive medications, there is promise for a growing 
population of women living with metastatic breast 
cancer.  Patients, family and carers should be provided 
with information and support/counselling regarding:
▪ Course of disease & associated anticancer 
treatments;
▪ Specific measures that could be available to relieve 
distressing symptoms; 
▪ Knowledge and application of services available; 
and
▪ Practical needs e.g. domestic help, financial, 
transport, emotional/spiritual needs.
Palliative care is to improve symptom control in 
association with psychological, social and spiritual well-
being of both the patient and the family.  Palliative care 
is provided in a multidisciplinary team approach. It 
is appropriate at any age and at any stage in cancers. 
Early integration palliative care into the standard cancer 
care allows better patient and caregiver outcomes & 
quality of life.
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Questions 1-10: Please answer T (true) or F (false) 
Breast cancers in Hong Kong – an overview from the Hong Kong Cancer Registry – Dr Roger KC NGAN
1. A genuine increase in the risk of developing breast cancer as measured by a rising age-standardised incidence 
rate among females is the main reason for the substantial increase in the number of new breast cancer cases in 
Hong Kong for the past 10 years.
2. The recent surge of new breast cancer cases is mostly observed in younger patients aged 30 – 45.
Hereditary Breast Cancer – Dr Ava KWONG
3. All offsprings of a BRCA mutation carrier, male or female will carry the BRCA mutation .
Update in Breast Imaging - Digital Breast Tomosynthesis (3D Mammogram) – Dr Chun-ying LUI
4. Reconstructed or synthesised 2D Mammogram from Digital Breast Tomosynthesis  in second generation 3D 
mammogram has image qualities comparable to a 2D Full Field Digital Mammogram. 
Update in surgical treatment in breast cancer – Dr Gebevueve CY CHEUNG and Dr Miranda CM CHAN
5. Use of preoperative core biopsy can decrease the need of re-operation and use of frozen section. 
Physiotherapy Management in Breast Cancer – Ms Rainbow Ka-yee LAW et al
6. Strengthening exercise of a lymphoedema-affected arm is not possible as it will make the lymphedema worse. 
Adjuvant and neoadjuvant therapy for breast cancer – Dr Joanne CHIU and Dr Henry SZE
7. Adjuvant targeted therapy against HER2 in combination with chemotherapy can effectively decrease the risk of 
breast cancer recurrence.
8. There is a trend to increase the overall radiotherapy treatment duration beyond 5 weeks to achieve a better 
disease control.
Management of Metastatic Breast Cancer (MBC) - Dr Tsz-kok YAU
9. For breast cancer patients with metastases at diagnosis, surgical resection of the primary tumour should be 
routinely offered to improve the survival.
Palliative Care for Patients with Metastatic Breast Cancer – When and How? - Dr Inda Sung SOONG
10. Early integration of palliative care into the standard cancer care in patients with advanced breast cancer allows 
better patient and caregiver outcomes & quality of life.
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The Galapagos …an experience of the lifetime
Dr Clement TH CHEN
MBChB (HK), FRCS (Edin), FCSHK, FHKAM (General Surgery)
Specialist in General Surgery
Associate Consultant, Division of Breast Surgery, Department of Surgery, The University of Hong Kong, Queen Mary Hospital
Dr Clement TH CHEN
The Galapagos is a group of volcanic Islands located on the 
Equator in the Pacific Ocean, hidden away from civilisation. 
Because of its isolation, it has developed its unique 
ecosystem that you can find nowhere else. It is within 
the border of Ecuador in South America. It is an exciting 
journey to naturalists to see the flora and fauna. And for 
a tourist like me, to be greeted by the friendliest birds, to 
dive and swim with penguins (in the Equator!), to observe 
the landscape evolved by nature and to see those endemic 
species like marine iguanas or giant Galapagos tortoises, it 
is like heaven on earth. No wonder, UNESCO designated 
Galapagos as the first World Heritage site in 1978.
To get there, you have to take a flight from Ecuador or 
Chile, which lasts about 2-3 hours. After you have landed, 
take a dinner on the waterfront while wild sea lions would 
just sit near accompanying you. I was astonished by their 
gigantic size to be pets but they are as eager to impress you 
with their loud howls to amuse their own kind.
The Galapagos consists of 18 main islands, located at the 
Galapagos triple junction. These islands move along the 
South American Plate at a rate of about 6cm per year. The 
first island was estimated to have formed at least 8 million 
years ago. With time, older islands would disappear into 
the sea. Island Isabela and Island Fernandina are relatively 
young and are still active with occasional eruptions. 
Others are ageing. Espanola, being the oldest island, is 
now inhabited by plants, followed by birds and reptiles 
gradually. The best way to explore the Galapagos is to go 
by sea, visiting each and every island in a period of one to 
two weeks. You could see a very different ecosystem on each 
island…It is no surprise therefore that this is where Charles 
Darwin was inspired and proposed the theory of Evolution. 
Mr Darwin neglected his medical studies, and came here 
during his voyage of the Beagle. He observed that the beaks 
of the finches differ among islands. He contributed it to 
be the process of natural selection, where only the fittest 
survives. The bird beaks adapted and evolved.
Now, let’s begin the journey of exploring this place. We 
shall start from the island, Santa Cruz in town of Puerto 
Ayora, where it has the largest human population. 
Alternatively, you can stay in San Cristobol, where the 
settlement begins. These are the usual places where 
materials are supplied all the way from the Latin American 
continent. Stay here for 1-2 days to enjoy your lovely hotel, 
to stroll along the street, or to sip a drink in the waterfront, 
and do buy some souvenirs. You can organise deep sea 
fishing here. Fish is abundant because of the convergence 
of three major oceanic currents that brings an incredible 
amount of marine life. 
However, if you are short of time, go to the fish market in 
the morning instead. The presence of big fish such as the 
enormous tuna and other big fish is quite a scene. You will 
be amused by the presence of pelicans that are also there, 
waiting patiently to share the catch of the day without 
actually doing the fishing themselves.
I arranged some scuba diving sessions there. It was a 
busy underwater scene. Numerous schools of fish. Fast 
swimming penguins. Small sharks. Colourful corals. This is 
a first class diving spot.
You can also sail to many islands depend on your time, 
budget and itinerary. I chose to use the Alta because it is an 
elegant and cozy motor boat. It carries only 16 passengers, 
an ideal size that you can get to know each passenger well. 
The boat takes you to the major spot sights you should 
visit. If you are under a budget, land based island hopping 
would be the alternative.
Now, let’s go sailing. The first island we are going to visit 
is Genovesa. It has the nickname of the bird island, where 
abundant red-footed boobies, Nazca boobies can be seen. In 
the nesting seasons, you can spot baby birds easily. 
The next stop would be Isabela and Fernandina. The living 
environment here is harsh and unforgiving with larva and 
few vegetation. Here, you can see the land and marine 
iguanas. The land iguanas can be huge! The endemic 
Galapagos marine iguana is the only reptile that has 
adapted and is able to swim in the ocean. The Galapagos 
cormorant (flightless cormorant) may not look loving with 
shabby feathers, but it has adapted radically that the flying 
ability is lost. 
Flightless 
cormorant
Land iguana Marine iguana 
and lava lizard
Then we will sail to Bartolome, where you can appreciate 
the volcanic landscape. You can see the penguins living 
in the Equator. It is so because of the cold current belt 
surrounding the island. You are welcome to join the fun and 
do snorkelling here. Don’t be surprised to find penguins 
dashing off like bullets beside you!
Santa Cruz hosts the largest population. Here you can 
appreciate the Scalesia forest. Scalesia is an endemic tree 
in Galapagos. There is also the Charles Darwin Research 
Station. Large giant tortoises are found here. The reserve 
centre helps hatching the tortoises’ eggs to raise their 
population. In the Black Turtle Cove, you can see large sting 
rays and small sharks. 
Our final stop would be remote yet the oldest island, 
Espanola. You can see it is richly inhabited by the various 
plants and animals. 
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Let’s briefly talk about a few interesting species. 
1) My favourite bird: the seabird Boobies. Like women 
who fancy different high heeled shoes, their feet also 
come in different bright colours like tortoise blue and 
red and elegant grey. These birds are very friendly 
and they are not photo shy. So have your camera 
ready, the birds are eager to show their cute little feet!
2) The marine iguanas. Iguanas are land animals. 
However, in the harsh environment filled only by 
lava, these iguanas get into the water to feed on 
green algae. There is a point to note, as they are cold-
blooded animals, facing the cold sea water of about 5 
degree Celsius, they have to feed faster because when 
the body temperature drops, they can be immobilised.
3) The Sally crabs. Unlike the green crabs we can find 
in Hong Kong, these are bright coloured crabs in red, 
orange, yellow and brown. They live along the lava 
shore. Besides feeding on green algae, they are also 
good friends to the marine iguanas by removing the 
ticks on their skin.
Sally crab   Sally crab and marine iguana
4) The native Galapagos tortoise. I could not imagine 
that tortoises can be so big. An adult one weighs up to 
250kg. Lonesome George was world famous, because 
it was the only sub-species tortoise left to extinct. I 
was glad that I could say hi to him before he left the 
world at an estimated age of 100 in year 2012 without 
producing any offspring.
The late Lonesome George
5) The Galapagos penguins. They are the only wild 
penguins that live at the Equator. This is because of 
the cold current in Galapagos.
6) The plants have to adapt to the difficult environments. 
So bushes and cacti or cactuses grow here. The 
dandelion also amazingly evolved and grew into a 
special kind of tree called scalesia.
The human activity had shaped the endemic species. 
First being the sailors and pirates who arrived here since 
1700, along with whalers and fur-seal hunters. Very sadly, 
they killed almost all of the tortoises close to the point of 
extinction for food and trade. Subsequently the government 
and NGOs put great effort to preserve the Galapagos. 
In addition, the 'El Niño' phenomenon, worsened by the 
global warming, causing the sea temperatures to rise 
dramatically, altered the algae growth. It killed 70% of the 
marine iguanas in starving to death in 1997-98 because they 
feed on algae only.
Every time I visited a nature reserve, be it the Amazon or 
the Galapagos, I see how the global climate change and 
human activities have great impacts on the ecosystem. It 
always serves as a good reminder that we should do my 
best to preserve our earth. After all, there is our one and 
only one planet. 
Dermatological Quiz
Dr Lai-yin CHONG
MBBS (HK), FRCP (Lond, Edin, Glasg), FHKCP, FHKAM (Med)
Specialist in Dermatology & Venereology
What are your preliminary diagnosis and differential diagnoses?
What is the usual bedside test that may be useful in establishing 
the diagnosis?
What are the geographical variation in its prevalence and clinical 
manifestations in Southern China?
What are the treatment options?
This 30-year-old Chinese female complained of recurrent painful oral 
and genital ulcerations for one year. There was no history of blistering 
before the erosions. She also recalled that once she had some painful 
nodules over both legs. Her past health was good. There was no 
significant drug history or preceding venereal exposure.
1.
2.
3.
4.
Questions:
(See P.40 for answers)
Fig.1:  Painful ulcer at lateral 
side of tongue
Fig.2:  Painful ulcers 
at right labium majus
Dr Lai-yin CHONG
Dermatological Quiz
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1:00 PM
HKMA CME Dept.
Tel: 2527 8452
2.5CME PointSAT19
MPS Workshop – Mastering Shared Decision Making
Venue: HKMA Central Premises, Dr. Li Shu Pui Professional Education Centre, 2/F, 
Chinese Club Building, 21-22 Connaught Road Central, Hong Kong
2:30 PM
Miss Hana YEUNG
Tel: 2527 8285
1 CME PointTUE15
HKMA Tai Po Community Network - Postmenopausal Osteoporosis Continuum: Why do 
We Start So Early?
Venue: Chiuchow Garden Restaurant(潮江春) Shop 001-003, 1/F, Uptown Plaza (新達廣場), 
No.9 Nam Wan Road, Tai Po 
1:45 PM
Ms. TAI / Ms. WONG
Tel: Ms. TAI: 3949 3430 / Ms. 
WONG 3949 3087
1 CME Point
THU17
KECN-HKCFP-UCH – Certificate Course for GPs 2015 (Session 4) – Common Skin Aging 
Problems
Venue: V Cuisine, 6/F., Holiday Inn Express Hong Kong Kowloon East, 3 Tong Tak Street, 
Tseung Kwan O 
1:00 PM
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Answers to Dermatological Quiz
Answer:
1. 
2.
3.
4.
Behcet’s syndrome
This disease was first described in 1924 by Hulusi Behcet, a 
Turkish dermatologist, consisted of a triad of recurrent oral 
aphthous ulcers, genital ulcers, and uveitis. 
The diagnostic criteria of Behcet (International Study 
Group) include:
Oral aphthosis (recurrent) + at least two of the following:
Genital (ulcer), ocular (uveitis), skin (erythema nodosum-
like or papulopustular eruption) and pathergy.
The differential diagnoses are chronic inflammatory bowel 
diseases, collagen-vascular diseases, herpes infection 
and Reiter’s disease. These must be excluded before the 
diagnosis is established.
Pathergy skin test
A positive result is defined as the formation of a sterile 
erythematous papule or pustule that appears 24-48 hours 
following the injection of 0.1ml normal saline intradermally 
at the forearm with a sterile needle of 20 gauge or smaller. A 
pathergy phenomenon reflects a hyper-reactivity response 
of the skin to scratches & intracutaneous needle punctures. 
However it is not diagnostic of the Behcet's syndrome. 
For instance, it is also invariably positive in pyoderma 
gangrenosum. Unfortunately, the sensitivity of this test 
is very low in Southern Chinese, making it seldom of any 
value in this group of population.
The Behcet's syndrome is also known as the “Silk road 
disease” from the East to the Mediterranean. It is most 
prevalent in Turkey, Iran, Saudi Arabia, Japan, Korea and 
Northern China. Interestingly there were considerable 
geographical  variation in prevalence and cl inical 
manifestations in Southern China including Hong Kong. For 
example, in Southern Chinese, the prevalence is rare, the 
commonest skin lesion is erythema nodosum-like eruptions 
instead of other skin manifestations, while the ocular 
involvement and other systemic involvements are much 
less common than in the Turks and Japanese. The specificity 
and sensitivity of the pathergy test is also much lower in 
Southern Chinese versus Turks and Japanese.
Treatment options include colchicine, dapsone, thalidomide, 
systemic corticosteroids, azathioprine, etc. It is now one 
of the well established indications for thalidomide. In 
recent years, tumour necrosis factor inhibitor therapy with 
infliximab and etanercept has also demonstrated varying 
degrees of success.
Dr Lai-yin CHONG 
MBBS (HK), FRCP (Lond, Edin, Glasg), FHKCP, FHKAM (Med)
Specialist in Dermatology & Venereology
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